Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell
mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such
as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's
bone marrow to the blood so they can be collected and stored.
Phase:
N/A
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Etoposide Etoposide phosphate JM 3100 Lenograstim Plerixafor